keyword
MENU ▼
Read by QxMD icon Read
search

Letrozol

keyword
https://www.readbyqxmd.com/read/29452160/orchiectomy-and-letrozole-differentially-regulate-synaptic-plasticity-and-spatial-memory-in-a-manner-that-is-mediated-by-src-1-in-the-hippocampus-of-male-mice
#1
Jikai Zhao, Chen Bian, Mengying Liu, Yangang Zhao, Tao Sun, Fangzhou Xing, Jiqiang Zhang
Hippocampal synaptic plasticity is the basis of spatial memory and cognition and is strongly regulated by both testicular androgens (testosterone, T) and hippocampal estrogens (17β-estradiol, E2) converted from T by aromatase, which is inhibited by letrozole (LET), but the contribution of each pathway to spatial memory and the associated mechanisms are unclear. In this study, we first used orchiectomy (ORX) and LET injection to investigate the effects of T and hippocampal E2 on spatial memory and hippocampal synaptic plasticity...
February 13, 2018: Journal of Steroid Biochemistry and Molecular Biology
https://www.readbyqxmd.com/read/29441507/economic-evaluation-of-fulvestrant-500-mg-compared-to-generic-aromatase-inhibitors-in-patients-with-advanced-breast-cancer-in-sweden
#2
Ugne Sabale, Mattias Ekman, Daniel Thunström, Claire Telford, Christopher Livings
OBJECTIVES: In Sweden, breast cancer (BC) represents 30% of newly diagnosed cancers and is the most common cancer in women. For hormone-dependent BC, endocrine therapies varying in efficacy and price are available. The aim of this study is to assess the cost effectiveness of fulvestrant 500 mg as a second-line hormonal therapy for postmenopausal women with estrogen receptor-positive metastatic or locally advanced BC versus letrozole, anastrozole, and exemestane in Sweden. METHODS: A three-state (pre-progression, post-progression, and death) partitioned-survival model was used to estimate progression-free (PFS) and overall survival (OS) by extrapolating trial results beyond the trial period to capture costs and benefits over a lifetime perspective...
December 2017: PharmacoEconomics Open
https://www.readbyqxmd.com/read/29437768/fda-approval-ribociclib-for-the-treatment-of-postmenopausal-women-with-hormone-receptor-positive-her2-negative-advanced-or-metastatic-breast-cancer
#3
Anand Shah, Erik Bloomquist, Shenghui Tang, Wentao Fu, Youwei Bi, Qi Liu, Jingyu Yu, Ping Zhao, Todd R Palmby, Kirsten B Goldberg, C J George Chang, Paresma Patel, Elleni Alebachew, Amy Tilley, William F Pierce, Amna Ibrahim, Gideon M Blumenthal, Rajeshwari Sridhara, Julia A Beaver, Richard Pazdur
On March 13, 2017, the U.S. Food and Drug Administration approved ribociclib (KISQALI, Novartis Pharmaceuticals Corp.), a cyclin-dependent kinase 4/6 inhibitor, in combination with an aromatase inhibitor as initial endocrine-based therapy for the treatment of postmenopausal women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer. The approval was based on a randomized, double-blind, placebo-controlled, international clinical trial (MONALEESA-2)...
February 7, 2018: Clinical Cancer Research: An Official Journal of the American Association for Cancer Research
https://www.readbyqxmd.com/read/29404806/first-line-ribociclib-plus-letrozole-in-postmenopausal-women-with-hr-%C3%A2-her2-%C3%A2-advanced-breast-cancer-tumor-response-and-pain-reduction-in-the-phase-3-monaleesa-2-trial
#4
Wolfgang Janni, Emilio Alba, Thomas Bachelot, Sami Diab, Miguel Gil-Gil, Thaddeus J Beck, Larisa Ryvo, Rafael Lopez, Michaela Tsai, Francisco J Esteva, Pilar Zamora Auñón, Zdenek Kral, Patrick Ward, Paul Richards, Timothy J Pluard, Santosh Sutradhar, Michelle Miller, Mario Campone
PURPOSE: The phase 3 MONALEESA-2 study demonstrated that addition of ribociclib (RIB) to letrozole (LET) significantly improved progression-free survival (PFS) in patients (pts) with hormone receptor-positive (HR+), HER2-negative (HER2-) advanced breast cancer (ABC). Here, we evaluated duration of response (DoR), tumor shrinkage, PFS by treatment-free interval (TFI), and health-related quality of life (HRQoL). METHODS: Postmenopausal women (N = 668) with HR+ , HER2- ABC and no prior systemic therapy for ABC were randomized to RIB (600 mg/day; 3 weeks on/1 week off) plus LET (2...
February 5, 2018: Breast Cancer Research and Treatment
https://www.readbyqxmd.com/read/29394793/-a-case-of-long-term-survival-of-breast-cancer-with-lymph-node-and-liver-metastases-treated-with-sequential-anti-her2-drugs-chemotherapy-and-endocrine-therapy
#5
Takashi Katsumori, Hisami Ohshima, Hiromitsu Hamaguchi, Shinichi Yamamoto, Yukika Tsukamoto, Tomohiro Iwanaga, Susumu Ohkawara
A 50s-year-old woman underwent left partial mastectomy with axillary lymphadenectomy for breast cancer. Histological examination indicated invasive ductal carcinoma, pT1c, pN0, Stage I , ly(+), ER(+), PgR(+). She received adjuvant therapy with tamoxifen and 50 Gy of irradiation to the residual breast. Four years after mastectomy, she was found to have left Rotter lymph node metastasis; then, anastrozole was administered instead of tamoxifen. Nine months later, she was found to have liver metastasis. Immunohistostaining revealed that the breast cancer was HER2-positive; she received AC followed by paclitaxel(PTX)with trastuzumab(T), and achieved complete response(CR)...
November 2017: Gan to Kagaku Ryoho. Cancer & Chemotherapy
https://www.readbyqxmd.com/read/29392438/letrozole-versus-clomiphene-citrate-in-polycystic-ovary-syndrome-a-meta-analysis-of-randomized-controlled-trials
#6
REVIEW
Shifu Hu, Qiong Yu, Yingying Wang, Mei Wang, Wei Xia, Changhong Zhu
PURPOSE: Polycystic ovary syndrome (PCOS) is a common endocrine disturbance affecting women in the reproductive age group. The present study aimed to compare the effects of letrozole (LE) and clomiphene citrate (CC) for ovulation induction in women with PCOS. METHODS: The PUBMED, Web of Science, and EMBASE databases were screened systematically for randomized controlled trials (RCTs) published from database inception to July 2017. RESULTS: Eleven RCTs involving 2255 patients were included, and data were independently extracted and analyzed using 95% risk ratios (RRs) and confidence intervals (CIs) based on a random- or fixed-effect model (as appropriate)...
February 1, 2018: Archives of Gynecology and Obstetrics
https://www.readbyqxmd.com/read/29383298/treatment-of-minimal-residual-disease-in-breast-cancer-a-longitudinal-case-study
#7
Nigel P Murray
The presence of micrometastatic disease will ultimately determine the breast cancer-specific mortality of patients treated according to current guidelines. Minimal residual disease (i.e., occult tumor, not detected by conventional tests) may exist in two forms: a dormant form of only micrometastasis and a more aggressive "awakened" form where CTCs (circulating tumor cells) are actively disseminating. The hypothesis is that patients with CTCs have a more advanced or aggressive disease (that the cancer has "awoken" and there is active dissemination), whereas those patients with only micrometastasis have "dormant" disease and, although at risk of future relapse, may not do so for many years...
July 27, 2017: Curēus
https://www.readbyqxmd.com/read/29375147/letrozole-vs-placebo-pretreatment-in-the-medical-management-of-first-trimester-missed-miscarriage-a-randomized-controlled-trial
#8
Haitham A Torky, Heba Marie, ElSayed ElDesouky, Samy Gebreel, Osama Raslan, Asem A Moussa, Ali M Ahmad, Eman Zain, Mohamed N Mohsen
Introduction: Misoprostol is used for the medical management of miscarriage as it is more effective in the early stages of pregnancy. Letrozole has an anti-estrogen effect and is used for the pretreatment of miscarriage with misoprostol. Aim: The aim of this study was compare the efficacy and safety of letrozole with placebo pretreatment in the medical management of first trimester missed miscarriage. Design: This was a prospective randomized case-control study...
January 2018: Geburtshilfe und Frauenheilkunde
https://www.readbyqxmd.com/read/29374415/-inhibitors-of-cyclin-dependent-kinases-cdk-a-new-group-of-medicines-in-therapy-of-advanced-breast-cancer
#9
EDITORIAL
Tomasz Sarosiek
Cyclin-dependent kinases (CDKs) are a family of enzyme proteins present in cell nuclei that regulate the various stages of the cell cycle. They act as proto-oncogens, and increased expression of some of these proteins (CDK4 and CDK6) is observed in breast cancer cells and associated with decreased sensitivity to anti-estrogen therapy. CDK inhibitors are chemicals that inhibit the enzymatic activity of specific CDKs. Currently three drugs in this group are available on the market and are registered for the treatment of advanced HR-positive, HER2-negative breast cancer...
January 23, 2018: Polski Merkuriusz Lekarski: Organ Polskiego Towarzystwa Lekarskiego
https://www.readbyqxmd.com/read/29371170/comparison-of-long-term-fertility-outcomes-after-myomectomy-relationship-with-number-of-fibroids-removed
#10
Shirley Shue, Milena Radeva, Tommaso Falcone
STUDY OBJECTIVE: To determine if the number of fibroids removed during myomectomy for symptomatic relief affects long-term fertility outcomes in reproductive aged women. DESIGN: Retrospective cohort survey study (Canadian Task Force classification II-2) SETTING: University hospital PATIENTS: One hundred forty-four patients who underwent myomectomy for symptomatic fibroids and attempted to conceive afterwards INTERVENTION: Questionnaire mailed to reproductive-aged women who received robotic, laparoscopic, or abdominal myomectomy MEASUREMENTS AND MAIN RESULTS: Patients with >6 fibroids removed were less likely to achieve pregnancy after myomectomy than patients with ≤6 fibroids removed (22...
January 22, 2018: Journal of Minimally Invasive Gynecology
https://www.readbyqxmd.com/read/29369111/the-impact-of-perioperative-hormonal-therapy-for-breast-cancer-on-transverse-rectus-abdominis-myocutaneous-flap-abdominal-complications
#11
Katherine M Huber, Eric Clayman, Ambuj Kumar, Paul Smith
BACKGROUND: The pedicled transverse rectus abdominis myocutaneous (TRAM) flap is a reliable reconstructive option in breast cancer patients; however, it carries known risk of donor site hernia formation. Some hormonal therapy drugs have been associated with hernia formation in animal models. Minimal data exist concerning impact of hormonal therapy for breast cancer on abdominal donor site complications after breast reconstruction. METHODS: Patients who underwent TRAM flap for breast cancer or high-risk status at a single institution by the senior author from 2003 to 2015 were identified...
January 24, 2018: Annals of Plastic Surgery
https://www.readbyqxmd.com/read/29364493/is-ovulation-induction-with-letrozole-in-breast-cancer-patients-still-safe-even-if-it-could-increase-progesterone-levels
#12
L Del Pup, F A Peccatori
Very high progesterone levels (mean 186.6 ± 43.6 ng/mL) during the luteal phase were found in a small study of breast cancers patients undergoing controlled ovarian stimulation (COS) with letrozole plus recombinant FSH. Results highlight the need to further evaluate this in larger series. While waiting, the clinical significance of high progesterone levels can be drawn from epidemiological and experimental data here reviewed in order to give reassurance to the clinician involved in fertility preservation. If the progesterone increase will be confirmed, epidemiological and experimental data do not seem to indicate a detrimental effect or they could even be protective...
January 2018: European Review for Medical and Pharmacological Sciences
https://www.readbyqxmd.com/read/29362313/-long-term-effect-of-fulvestrant-for-locally-advanced-breast-cancer-in-an-elderly-patient-a-case-report
#13
Kenichi Sakurai, Shigeru Fujisaki, Hitomi Kubota, Yukiko Hara, Shuhei Suzuki, Keita Adachi, Ryouichi Tomita, Katsuhisa Enomoto, Tomohiro Hirano
We report an elderly patient with locally advanced breast cancer who received long-term fulvestrant therapy.The patient was a 75-year-old woman who presented with a right breast lump.She noticed the tumor 4 years and 6 months ago, but she had not visited any hospital.However, her daughter brought her to our hospital.The tumor was 73mm in diameter.A core needle biopsy for breast tumor led to a diagnosis of an invasive ductal carcinoma, positive for estrogen receptor(ER)and progesterone receptor(PgR), and negative for HER2/neu...
January 2018: Gan to Kagaku Ryoho. Cancer & Chemotherapy
https://www.readbyqxmd.com/read/29360932/impact-of-palbociclib-plus-letrozole-on-patient-reported-health-related-quality-of-life-results-from-the-paloma-2-trial
#14
H S Rugo, V Diéras, K A Gelmon, R S Finn, D J Slamon, M Martin, P Neven, Y Shparyk, A Mori, D R Lu, H Bhattacharyya, C Huang Bartlett, S Iyer, S Johnston, J Ettl, N Harbeck
Background: Patient-reported outcomes are integral in benefit-risk assessments of new treatment regimens. The PALOMA-2 study provides the largest body of evidence for patient-reported health-related quality of life (HRQOL) for patients with metastatic breast cancer receiving first-line endocrine-based therapy (palbociclib plus letrozole and letrozole alone). Patients and Methods: Treatment-naïve postmenopausal women with estrogen receptor-positive (ER+)/human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer were randomized 2:1 to palbociclib plus letrozole (n=444) or placebo plus letrozole (n=222)...
January 19, 2018: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/29360661/palbociclib-has-no-clinically-relevant-effect-on-the-qtc-interval-in-patients-with-advanced-breast-cancer
#15
Chandrasekar Durairaj, Ana Ruiz-Garcia, Eric R Gauthier, Xin Huang, Dongrui R Lu, Justin T Hoffman, Richard S Finn, Anil A Joy, Johannes Ettl, Hope S Rugo, Jenny Zheng, Keith D Wilner, Diane D Wang
The aim of this study was to assess the potential effects of palbociclib in combination with letrozole on QTc. PALOMA-2, a phase 3, randomized, double-blind, placebo-controlled trial, compared palbociclib plus letrozole with placebo plus letrozole in postmenopausal women with estrogen receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer. The study included a QTc evaluation substudy carried out as a definitive QT interval prolongation assessment for palbociclib. Time-matched triplicate ECGs were performed at 0, 2, 4, 6, and 8 h at baseline (Day 0) and on Cycle 1 Day 14...
January 22, 2018: Anti-cancer Drugs
https://www.readbyqxmd.com/read/29354951/-acupuncture-and-chinese-medicine-of-artificial-cycle-therapy-for-insulin-resistance-of-polycystic-ovary-syndrome-with-phlegm-damp-type-and-its-mechanism
#16
Juan Yang, Ying Liu, Jian Huang, Jinbang Xu, Xiumi You, Qiuping Lin, Junxin Zhang, Jingjing Dun, Shan Huang
OBJECTIVE: To explore the effect difference between acupuncture combined with Chinese medicine of artificial cycle therapy on the basis of western medication and simple western medication for polycystic ovarian syndrome (PCOS) of phlegm damp type with insulin resistance, and to explore its mechanism. METHODS: Sixty patients were randomly assigned into an observation group and a control group, 30 cases in each group. Patients of the control group began to take letrozole and metformin orally on the third menstrual day...
November 12, 2017: Zhongguo Zhen Jiu, Chinese Acupuncture & Moxibustion
https://www.readbyqxmd.com/read/29354933/-clinical-therapeutic-effects-of-acupuncture-combined-with-chinese-herbal-medicine-on-infertility-of-polycystic-ovary-syndrome-in-the-patients-with-ovulation-induction-with-letrozole
#17
Yan Yin, Yingchun Zhang, Hua Zhang, Duosheng Jiang, Guirong Guo
OBJECTIVE: To evaluate the clinical therapeutic effects and safety on infertility of polycystic ovary syndrome (PCOS) in the patients with ovulation induction with letrozole in the treatment with the formula for regulating menstruation and removing phlegm and electroacupuncture (EA). METHODS: A total of 120 patients of PCOS infertility were randomized into 3 groups, 40 cases in each one. In the group A, diane-35 was prescribed for oral administration (one tablet a day since the 5th day of menstruation, continuously for 21 days)...
January 12, 2018: Zhongguo Zhen Jiu, Chinese Acupuncture & Moxibustion
https://www.readbyqxmd.com/read/29345736/palbociclib-in-combination-with-letrozole-as-first-line-treatment-for-advanced-breast-cancer-a-japanese-phase-ii-study
#18
Norikazu Masuda, Reiki Nishimura, Masato Takahashi, Kenichi Inoue, Shinji Ohno, Hiroji Iwata, Yuko Mori, Satoshi Hashigaki, Yasuaki Muramatsu, Takashi Nagasawa, Yoshiko Umeyama, Masakazu Toi
This single-arm, open-label, phase II study in 42 Japanese postmenopausal patients with estrogen receptor-positive/human epidermal growth factor receptor 2-negative (ER+/HER2-) advanced breast cancer evaluated the efficacy, safety, and pharmacokinetics of first-line palbociclib (125 mg once daily, 3 weeks on/1 week off) coadministered with letrozole (2.5 mg once daily). The primary endpoint of investigator-assessed 1-year progression-free survival probability was 75.0% (90% CI, 61.3%-84.4%), far surpassing the 40% lower limit of the 90% CI supporting efficacy...
January 18, 2018: Cancer Science
https://www.readbyqxmd.com/read/29344106/overall-survival-and-progression-free-survival-with-endocrine-therapy-for-hormone-receptor-positive-her2-negative-advanced-breast-cancer-review
#19
REVIEW
Tomás Reinert, Carlos H Barrios
We reviewed randomized phase II/III trials comparing first- or second-line endocrine therapy as monotherapy or in combination with targeted therapies for treatment of postmenopausal patients with hormone receptor-positive advanced breast cancer. First-line was defined as treatment for endocrine therapy-naïve advanced breast cancer or advanced disease treated with endocrine therapy in the adjuvant/neoadjuvant setting. Second-line was defined as endocrine therapy for advanced breast cancer following disease progression on endocrine therapy for advanced disease...
November 2017: Therapeutic Advances in Medical Oncology
https://www.readbyqxmd.com/read/29343615/growth-of-human-breast-cancers-in-peromyscus
#20
Vimala Kaza, Elena Farmaki, Amanda Havighorst, Janet Crossland, Ioulia Chatzistamou, Hippokratis Kiaris
Modeling breast cancer in general and hormone-sensitive breast cancer, in particular in mice, has several limitations. These are related to the inbred nature of laboratory mice, and do not allow adequate appreciation of the contribution of the host's genetic heterogeneity in tumor growth. In addition, the naturally low estrogen levels of mice makes estradiol supplementation obligatory for tumor growth. Here, we show that Peromyscus californicus, following cyclosporine-mediated immunosuppression, supports the growth of both MDA-MB-231 estrogen-independent and MCF7 estrogen receptor-positive breast cancers without exogenous estradiol supplementation...
January 17, 2018: Disease Models & Mechanisms
keyword
keyword
48622
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"